本页面由Tiger Trade Technology Pte. Ltd.提供服务

Tarsus Pharmaceuticals, Inc.

70.82
-3.5800-4.81%
盘后:70.05-0.7700-1.09%16:46 EDT
成交量:120.89万
成交额:8,692.46万
市值:31.08亿
市盈率:-65.43
高:75.02
开:74.50
低:70.32
收:74.40
52周最高:91.53
52周最低:53.89
股本:4,388.30万
流通股本:3,563.83万
量比:1.70
换手率:3.39%
股息:- -
股息率:- -
每股收益(TTM):-1.0824
每股收益(LYR):-1.5900
净资产收益率:-13.68%
总资产收益率:-5.48%
市净率:8.96
市盈率(LYR):-44.54

数据加载中...

2024/05/08

季度报告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2024/05/08

重要事件披露

Form 8-K - Current report
2024/04/23

重要事件披露

Form 8-K - Current report
2024/04/12

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/03/29

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/03/19

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/03/19

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/03/19

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/03/19

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/03/19

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/03/05

重要事件披露

Form 8-K - Current report
2024/03/01

重要事件披露

Form 8-K - Current report
2024/02/27

员工持股计划

Form S-8 - Securities to be offered to employees in employee benefit plans
2024/02/27

年度报告

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
2024/02/27

重要事件披露

Form 8-K - Current report
2024/02/15

超过5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
2024/02/15

超过5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
2024/02/14

超过5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
2024/02/14

超过5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
2024/02/02

超过5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]